The aim of this study was to explore postoperative changes in prostate-specific antigen (PSA) levels and risk factors that influence the clinical effects of ultrasound-guided permanent [(125)I] seed implantation in the treatment of prostate cancer.
From July 2009 to December 2012, 41 prostate cancer patients who underwent transrectal ultrasound-guided [(125)I] seed implantation were followed up for 3-56 months. The patients were divided into 2 groups according to their results: group A, benign rebound group, 31 cases; and group B, biochemical relapse group, 10 cases. A blood analysis of group A showed that the initial PSA rise after a nadir occurred postoperatively at 16.8 ± 1.2 months, and in 65.8% (27/41) patients the rise occurred during 15-27 weeks.
For group B, the initial PSA rise after a nadir occurred postoperatively at 30.2 ± 2.1 months, and the difference in the time parameter of the initial PSA rise after the nadir was statistically significant between the 2 groups (P < 0.01). During treatment, age was shown to be a risk factor for group A (P = 0.0027, P < 0.01). Postoperative changes in PSA levels after ultrasound-guided permanent [(125)I] seed implantation contributed to the assessment of the clinical treatment effects.
Genet Mol Res. 2015 Jun 29;14(2):7142-50. doi: 10.4238/2015.June.29.8.
Bian XL1, Wang CZ2, Wang Y1, Li YN3, Zhang LZ3, Liu L3.
1 Department of Ultrasound, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
2 Department of Ultrasound, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China
3 Department of Cardiovascular Ultrasound, Henan Province People's Hospital, Zhengzhou, China.